

VPA10475/032/002

Spizobactin 1,500,000 IU / 250 mg chewable tablets for dogs

Variation	Summary	Date
Vet - B38	VNRA - Vet - B38 - Change in pack size (number of units e.g. tablets, ampoules, etc. in a pack) within the range of the currently approved pack size - B38 Changes to the quality part of the dossier: Change in pack size (number of units e.g. tablets, ampoules, etc. in a pack) within the range of the currently approved pack size. In cases where a given pack size has received an individual marketing authorisation which is separate to the marketing authorisation for other pack sizes of the same product, the change of the former will not be a variation according to Article 61, but a variation according to Article 62 of Regulation (EU) 2019/6	17/04/24
Vet - B20	VNRA - Vet - B20 - Replacement or addition of a primary packaging site of a non-sterile finished product - B20 Changes to the quality part of the dossier: Replacement or addition of a primary packaging site of a non-sterile finished product	15/01/24
Vet - B21	VNRA - Vet - B21 - Replacement or addition of a secondary packaging site of a finished product - B21 Changes to the quality part of the dossier: Replacement or addition of a secondary packaging site of a finished product	15/01/24
Vet - B24	VNRA - Vet - B24 - Replacement or addition of a manufacturer responsible for batch release including batch control or testing of a non- sterile finished product - B24 Changes to the quality part of the dossier: Replacement or addition of a manufacturer responsible for batch release including batch control or testing of a non- sterile finished product	15/01/24
Vet - B45	VNRA - Vet - B45 - Submission of a new Ph. Eur. CEP from a new manufacturer (replacement or addition) for a non-sterile active substance, starting material, reagent or intermediate, excipient - B45 Changes to the quality part of the dossier: Submission of a new Ph. Eur. CEP from a new manufacturer (replacement or addition) for a non-sterile: — active substance; — starting material, reagent or intermediate used in the manufacturing process of the active substance; — excipient	15/01/24
Vet - F.II.b.5 z)	VRA-R - Vet - F.II.b.5 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.b.5 z) Quality Changes - Finished Product -Manufacture - Change to in-process tests or limits applied during the manufacture of the finished product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	15/01/24
Vet - F.II.b.5 z)	VRA-R - Vet - F.II.b.5 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.b.5 z) Quality Changes - Finished Product -Manufacture - Change to in-process tests or limits	15/01/24

	applied during the manufacture of the finished product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	
Vet - F.II.b.1 c)	VRA-S - Vet - F.II.b.1 c) - c) Site where any manufacturing operation(s) take place, except batch-release, batch control, primary and secondary packaging, for non-sterile medicinal products - F.II.b.1 c) Quality Changes - Finished Product -Manufacture - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - Site where any manufacturing operation(s) take place, except batch-release, batch control, primary and secondary packaging, for non-sterile medicinal products	15/01/24
Vet - B44	VNRA - Vet - B44 - Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile active substance, starting material, reagent or intermediate, excipient - B44 Changes to the quality part of the dossier: Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile: — active substance; — starting material, reagent or intermediate used in the manufacturing process of the active substance; — excipient	28/11/23